CareDx Debt to Equity Ratio 2013-2025 | CDNA
Current and historical debt to equity ratio values for CareDx (CDNA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. CareDx debt/equity for the three months ending March 31, 2025 was 0.00.
| CareDx Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $0.11B | $0.38B | 0.29 |
| 2024-12-31 | $0.11B | $0.38B | 0.30 |
| 2024-09-30 | $0.20B | $0.27B | 0.75 |
| 2024-06-30 | $0.20B | $0.27B | 0.76 |
| 2024-03-31 | $0.20B | $0.26B | 0.77 |
| 2023-12-31 | $0.21B | $0.26B | 0.79 |
| 2023-09-30 | $0.11B | $0.39B | 0.27 |
| 2023-06-30 | $0.11B | $0.41B | 0.27 |
| 2023-03-31 | $0.11B | $0.42B | 0.26 |
| 2022-12-31 | $0.11B | $0.43B | 0.26 |
| 2022-09-30 | $0.11B | $0.44B | 0.25 |
| 2022-06-30 | $0.10B | $0.44B | 0.22 |
| 2022-03-31 | $0.09B | $0.46B | 0.20 |
| 2021-12-31 | $0.10B | $0.47B | 0.22 |
| 2021-09-30 | $0.09B | $0.47B | 0.19 |
| 2021-06-30 | $0.08B | $0.48B | 0.16 |
| 2021-03-31 | $0.07B | $0.47B | 0.15 |
| 2020-12-31 | $0.09B | $0.28B | 0.33 |
| 2020-09-30 | $0.09B | $0.27B | 0.32 |
| 2020-06-30 | $0.08B | $0.26B | 0.32 |
| 2020-03-31 | $0.06B | $0.10B | 0.55 |
| 2019-12-31 | $0.05B | $0.10B | 0.53 |
| 2019-09-30 | $0.05B | $0.10B | 0.49 |
| 2019-06-30 | $0.05B | $0.09B | 0.53 |
| 2019-03-31 | $0.03B | $0.10B | 0.34 |
| 2018-12-31 | $0.04B | $0.10B | 0.36 |
| 2018-09-30 | $0.05B | $0.04B | 1.06 |
| 2018-06-30 | $0.05B | $0.03B | 1.76 |
| 2018-03-31 | $0.05B | $0.03B | 1.36 |
| 2017-12-31 | $0.09B | $-0.01B | -15.04 |
| 2017-09-30 | $0.08B | $0.00B | -430.10 |
| 2017-06-30 | $0.07B | $0.01B | 5.49 |
| 2017-03-31 | $0.07B | $0.02B | 4.41 |
| 2016-12-31 | $0.06B | $0.02B | 2.88 |
| 2016-09-30 | $0.07B | $0.04B | 1.78 |
| 2016-06-30 | $0.07B | $0.03B | 2.09 |
| 2016-03-31 | $0.03B | $0.02B | 1.39 |
| 2015-12-31 | $0.03B | $0.03B | 0.89 |
| 2015-09-30 | $0.03B | $0.03B | 0.75 |
| 2015-06-30 | $0.03B | $0.04B | 0.67 |
| 2015-03-31 | $0.02B | $0.04B | 0.60 |
| 2014-12-31 | $0.02B | $0.04B | 0.48 |
| 2014-09-30 | $0.02B | $0.04B | 0.53 |
| 2014-06-30 | $0.04B | $0.00B | -24.19 |
| 2014-03-31 | $0.03B | $-0.02B | -1.66 |
| 2013-12-31 | $0.03B | $-0.02B | -1.64 |
| 2013-09-30 | $0.00B | $0.00B | 0.00 |
| 2013-06-30 | $0.00B | $0.00B | 0.00 |
| 2013-03-31 | $0.00B | $0.00B | 0.00 |
| 2012-12-31 | $0.02B | $-0.01B | -1.82 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.944B | $0.334B |
| CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $132.070B | 24.77 |
| Elevance Health (ELV) | United States | $84.109B | 10.85 |
| CVS Health (CVS) | United States | $76.951B | 9.56 |
| Cencora (COR) | United States | $56.664B | 19.71 |
| DiDi Global (DIDIY) | China | $22.591B | 34.29 |
| Natera (NTRA) | United States | $20.935B | 0.00 |
| BioMerieux (BMXMF) | France | $15.355B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.529B | 0.00 |
| Solventum (SOLV) | United States | $12.251B | 12.97 |
| CochLear (CHEOY) | Australia | $11.298B | 0.00 |
| Revvity (RVTY) | United States | $10.529B | 18.12 |
| ICON (ICLR) | Ireland | $10.336B | 9.61 |
| Viatris (VTRS) | United States | $9.730B | 3.34 |
| Doximity (DOCS) | United States | $9.525B | 44.37 |
| Avantor (AVTR) | United States | $8.647B | 12.56 |
| HealthEquity (HQY) | United States | $8.564B | 42.13 |
| Medpace Holdings (MEDP) | United States | $8.476B | 22.51 |
| Sonic Healthcare (SKHHY) | Australia | $8.176B | 0.00 |
| Charles River Laboratories (CRL) | United States | $6.716B | 13.16 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| BrightSpring Health Services (BTSG) | United States | $4.048B | 37.47 |
| Bausch + Lomb (BLCO) | Canada | $3.990B | 23.52 |
| Sotera Health (SHC) | United States | $3.452B | 19.61 |
| Surgery Partners (SGRY) | United States | $2.922B | 38.00 |
| Alignment Healthcare (ALHC) | United States | $2.865B | 0.00 |
| Concentras Parent (CON) | United States | $2.710B | 15.66 |
| Organon (OGN) | United States | $2.259B | 2.40 |
| Ardent Health Partners (ARDT) | United States | $2.091B | 8.91 |
| GeneDx Holdings (WGS) | United States | $2.043B | 78.68 |
| Premier (PINC) | United States | $1.899B | 14.41 |
| Progyny (PGNY) | United States | $1.759B | 38.72 |
| PACS (PACS) | United States | $1.497B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.336B | 26.71 |
| Teladoc Health (TDOC) | United States | $1.195B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.165B | 8.86 |
| Establishment Labs Holdings (ESTA) | $1.059B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| Agilon Health (AGL) | United States | $0.919B | 0.00 |
| Nutex Health (NUTX) | United States | $0.890B | 13.45 |
| AMN Healthcare Services Inc (AMN) | United States | $0.795B | 7.44 |
| QDM (QDMI) | Hong Kong, SAR China | $0.743B | 0.00 |
| Embecta (EMBC) | United States | $0.626B | 4.22 |
| InnovAge Holding (INNV) | United States | $0.531B | 0.00 |
| LifeMD (LFMD) | United States | $0.524B | 0.00 |
| Enhabit (EHAB) | United States | $0.518B | 42.58 |
| Auna S.A (AUNA) | Luxembourg | $0.492B | 11.08 |
| SBC Medicals (SBC) | United States | $0.471B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.462B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.405B | 0.00 |
| Oncology Institute (TOI) | United States | $0.228B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.215B | 0.00 |
| Beauty Health (SKIN) | United States | $0.202B | 0.00 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| DocGo (DCGO) | United States | $0.137B | 22.33 |
| OncoCyte (OCX) | United States | $0.096B | 0.00 |
| So-Young (SY) | China | $0.087B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.066B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.061B | 0.00 |
| NeueHealth (NEUE) | United States | $0.060B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.059B | 0.00 |
| Biodesix (BDSX) | United States | $0.050B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.043B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.031B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.025B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| ModivCare (MODV) | United States | $0.013B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.010B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |